Day One Bio Files 8-K, Confirms Nasdaq Listing Under DAWN

Ticker: DAWN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1845337

Complexity: simple

Sentiment: neutral

Topics: corporate-governance, regulatory-filing, exchange-listing

TL;DR

**Day One Bio (DAWN) filed a routine 8-K, confirming its Nasdaq listing.**

AI Summary

Day One Biopharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on the Nasdaq Global Select Market under the ticker DAWN. This filing, while routine, is important for investors as it reaffirms the company's compliance with SEC regulations and its continued listing, providing transparency and stability for those who own or are considering buying DAWN stock.

Why It Matters

This filing confirms Day One Biopharmaceuticals' ongoing compliance with SEC reporting requirements and its active listing on the Nasdaq Global Select Market, which is crucial for investor confidence and market liquidity.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not contain any information that would significantly alter the company's risk profile.

Analyst Insight

This is a routine administrative filing. A smart investor would note the confirmation of listing details but recognize that this filing alone does not provide new material information for investment decisions. It's a good sign of ongoing compliance.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Day One Biopharmaceuticals, Inc.?

The primary purpose of this 8-K filing, dated January 8, 2024, is to provide current report information pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically under Item 5.02 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits, confirming general corporate details and its listing on the Nasdaq Global Select Market.

On which stock exchange is Day One Biopharmaceuticals, Inc. listed, and what is its trading symbol?

Day One Biopharmaceuticals, Inc. is listed on the Nasdaq Global Select Market, and its trading symbol is DAWN, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the state of incorporation for Day One Biopharmaceuticals, Inc.?

Day One Biopharmaceuticals, Inc. is incorporated in Delaware, as indicated in the filing under 'State or other jurisdiction of incorporation'.

What is the business address and telephone number of Day One Biopharmaceuticals, Inc. as reported in this filing?

The business address of Day One Biopharmaceuticals, Inc. is 2000 Sierra Point Parkway, Suite 501, Brisbane, California, 94005, and its telephone number is (650) 484-0899, according to the filing's 'BUSINESS ADDRESS' section.

What is the par value per share of the Common Stock for Day One Biopharmaceuticals, Inc.?

The par value per share of the Common Stock for Day One Biopharmaceuticals, Inc. is $0.0001, as specified in the filing under 'Title of each class' for 'Common Stock, par value $0.0001 per share'.

Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-01-08 08:30:42

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. As previously announced, on January 8, 2024, Day One Biopharmaceuticals, Inc. (the "Company") will participate in the 42 nd Annual J.P. Morgan Healthcare Conference (the "JPM Conference"). A copy of the Company's presentation materials for the JPM Conference is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Also on January 8, 2024, the Company updated its corporate presentation in connection with its participation in the JPM Conference. A copy of the updated corporate presentation materials is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01, including Exhibits 99.1 and 99.2 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01 and in the accompanying Exhibits 99.1 and 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 J.P. Morgan Healthcare Conference Presentation 99.2 Corporate Presentation 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: January 8, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing